SYNH - INCリサ―チ・ホ―ルディングス （Syneos Health Inc.）SYNHのニュース
FivepHusion team up with Treehill Partners and Syneos Health 2023/05/26 11:00:26 Seeking Alpha
FivepHusion has collaboration with Treehill Partners, a New York-based strategic and financial advisory firm specializing in healthcare industry transactions, and Syneos Health (SYNH)…
Veeva Systems: Biopharma Leaders Connect at Veeva R&D and Quality Summit to Advance Innovation for the Industry and Patients 2023/05/24 11:06:00 Finanz Nachrichten
Bayer, Boehringer Ingelheim, GSK, LEO Pharma, Recordati, Syneos Health and more share learnings on driving efficiency across the product development lifecycle BARCELONA, Spain, May 24, 2023 /PRNew…
Life Line Screening Announces Kevin Vass as Chief Financial Officer 2023/05/18 17:30:00 Benzinga
Life Line Screening, the nation''s leading mobile preventive health screening company for cardiovascular disease and stroke risk, announces the expansion of its leadership team with Kevin Vass joining the organization as Chief Financial Officer. Mr. Vass comes with key experience from his time as Divisional Chief Financial Officer at Harman International, a Samsung company, Chief Financial Officer of StudyKIK, and most recently, Technology and Data Solutions Chief Financial Officer at Syneos Health. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230518005242/en/ Kevin Vass, CFO of Life Line Screening (Photo: Business Wire) "I am thrilled to be … Full story available on Benzinga.com
Syneos Health Target Price Raised Amid $7.1B Acquisition News: Analyst Provides Insight 2023/05/16 18:34:55 Benzinga
Mizuho analyst Ann Hynes reiterated a Neutral rating on the shares of Syneos Health, Inc. (NASDAQ: SYNH ), raising the price target to $43 from $38 . The company recently announced a definitive agreement to be purchased by a group of private equity firms led by Elliott Investment Management for $7.1 billion, including the assumption of all debt. The price target has been raised, focusing on the pending acquisition deal. Also … Full story available on Benzinga.com
Mizuho Securities maintains Syneos Health at ''buy'' with a price target of $43.00 2023/05/16 10:38:42 Investing.com
https://www.investing.com/news/pro/inc-research-holdings-inc-receives-investment-bank-analyst-rating-update-3083547
FivepHusion team up with Treehill Partners and Syneos Health 2023/05/26 11:00:26 Seeking Alpha
FivepHusion has collaboration with Treehill Partners, a New York-based strategic and financial advisory firm specializing in healthcare industry transactions, and Syneos Health (SYNH)…
Veeva Systems: Biopharma Leaders Connect at Veeva R&D and Quality Summit to Advance Innovation for the Industry and Patients 2023/05/24 11:06:00 Finanz Nachrichten
Bayer, Boehringer Ingelheim, GSK, LEO Pharma, Recordati, Syneos Health and more share learnings on driving efficiency across the product development lifecycle BARCELONA, Spain, May 24, 2023 /PRNew…
Life Line Screening Announces Kevin Vass as Chief Financial Officer 2023/05/18 17:30:00 Benzinga
Life Line Screening, the nation''s leading mobile preventive health screening company for cardiovascular disease and stroke risk, announces the expansion of its leadership team with Kevin Vass joining the organization as Chief Financial Officer. Mr. Vass comes with key experience from his time as Divisional Chief Financial Officer at Harman International, a Samsung company, Chief Financial Officer of StudyKIK, and most recently, Technology and Data Solutions Chief Financial Officer at Syneos Health. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230518005242/en/ Kevin Vass, CFO of Life Line Screening (Photo: Business Wire) "I am thrilled to be … Full story available on Benzinga.com
Syneos Health Target Price Raised Amid $7.1B Acquisition News: Analyst Provides Insight 2023/05/16 18:34:55 Benzinga
Mizuho analyst Ann Hynes reiterated a Neutral rating on the shares of Syneos Health, Inc. (NASDAQ: SYNH ), raising the price target to $43 from $38 . The company recently announced a definitive agreement to be purchased by a group of private equity firms led by Elliott Investment Management for $7.1 billion, including the assumption of all debt. The price target has been raised, focusing on the pending acquisition deal. Also … Full story available on Benzinga.com
Mizuho Securities maintains Syneos Health at ''buy'' with a price target of $43.00 2023/05/16 10:38:42 Investing.com
https://www.investing.com/news/pro/inc-research-holdings-inc-receives-investment-bank-analyst-rating-update-3083547
FivepHusion team up with Treehill Partners and Syneos Health 2023/05/26 11:00:26 Seeking Alpha
FivepHusion has collaboration with Treehill Partners, a New York-based strategic and financial advisory firm specializing in healthcare industry transactions, and Syneos Health (SYNH)…
Veeva Systems: Biopharma Leaders Connect at Veeva R&D and Quality Summit to Advance Innovation for the Industry and Patients 2023/05/24 11:06:00 Finanz Nachrichten
Bayer, Boehringer Ingelheim, GSK, LEO Pharma, Recordati, Syneos Health and more share learnings on driving efficiency across the product development lifecycle BARCELONA, Spain, May 24, 2023 /PRNew…
Life Line Screening Announces Kevin Vass as Chief Financial Officer 2023/05/18 17:30:00 Benzinga
Life Line Screening, the nation''s leading mobile preventive health screening company for cardiovascular disease and stroke risk, announces the expansion of its leadership team with Kevin Vass joining the organization as Chief Financial Officer. Mr. Vass comes with key experience from his time as Divisional Chief Financial Officer at Harman International, a Samsung company, Chief Financial Officer of StudyKIK, and most recently, Technology and Data Solutions Chief Financial Officer at Syneos Health. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230518005242/en/ Kevin Vass, CFO of Life Line Screening (Photo: Business Wire) "I am thrilled to be … Full story available on Benzinga.com
Syneos Health Target Price Raised Amid $7.1B Acquisition News: Analyst Provides Insight 2023/05/16 18:34:55 Benzinga
Mizuho analyst Ann Hynes reiterated a Neutral rating on the shares of Syneos Health, Inc. (NASDAQ: SYNH ), raising the price target to $43 from $38 . The company recently announced a definitive agreement to be purchased by a group of private equity firms led by Elliott Investment Management for $7.1 billion, including the assumption of all debt. The price target has been raised, focusing on the pending acquisition deal. Also … Full story available on Benzinga.com